MDD Drug Dropped by AstraZeneca, Targacept After Phase III Failures

March 27, 2012
AstraZeneca (AZ) and Targacept are pulling the plug on their investigational drug for major depressive disorder (MDD), TC-5214, after two more Phase III trials came up short. AZ will accept an impairment charge of $50 million on the failure of the program, which produced a string of missed endpoints starting with the first Phase III efficacy/tolerability trial.
Washington Drug Letter